PharmiWeb.com - Global Pharma News & Resources
16-Sep-2019

Novartis formally announces TALON, a global clinical trial in wet AMD comparing brolucizumab vs aflibercept in two primary endpoints

  • Phase IIIb TALON clinical trial’s two primary endpoints are superiority for brolucizumab in treatment interval duration and non-inferiority in change in visual acuity[i] 
  • Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resolution and CST fluctuationi
  • Uses “treat-to-control” regimen allowing physicians to extend treatment intervals up to 16 weeks based on response to diseasei
  • TALON is a 64-week, two-arm, randomized double-masked study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mgi
  • TALON will have seven UK trial sites and complements current clinical dataset by generating new evidence on the efficacy of brolucizumab for the treatment of wet age-related macular degenerationi

Dr Mark Toms, Chief Scientific Officer at Novartis Pharmaceuticals UK said, “HAWK and HARRIER reinforced our confidence in brolucizumab as an important scientific advancement. The initiation of TALON provides the opportunity to gather further data and will assess superiority for brolucizumab in treatment interval duration.” 

“Wet AMD is a chronic condition and the need for frequent injections and clinic visits can often lead to under-treatment and suboptimal visual outcomes,” said Robin Hamilton, lead investigator of TALON and Consultant Ophthalmic Surgeon at Moorfields Eye Hospital. “Results from HAWK and HARRIER suggested that brolucizumab has the potential to allow early longer injection intervals with comparable visual outcomes to aflibercept. Using a “treat-to-control” regimen, TALON will investigate brolucizumab for superiority versus aflibercept in duration of treatment interval, as well as non-inferiority in change in visual acuity.”

More information can be found on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04005352  


[i] ClinicalTrials.gov. Identifier NCT04005352. Available at: https://clinicaltrials.gov/ct2/show/NCT04005352. Accessed September 2019.

Editor Details

  • Company:
    • Novartis Pharmaceuticals
  • Name:
    • Novartis Pharmaceuticals
Last Updated: 16-Sep-2019